Apremilast

Details

Files

Generic Name:

Apremilast

Project Status:

Complete

Therapeutic Area:

Psoriasis, moderate to severe plaque

Manufacturer:

Celgene

Call for patient/clinician input open:

January 29, 2016

Brand Name:

Otezla

Project Line:

Reimbursement Review

Project Number:

SR0478-000

Call for patient/clinician input closed:

March 21, 2016

NOC Status at Filing:

Post NOC

Performance Metric:

Achieved

Submission Type:

Resubmission

Indications:

Psoriasis, moderate to severe plaque

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

October 26, 2016

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Patient Group Input Submissions View PDF

Clinical Report View PDF

Pharmacoeconomic Report View PDF

Last Updated : January 29, 2016